Drug Trial Radar · NCT06063057
Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial
Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
744
Actual
Start
Sep 20, 2023
Primary completion
Dec 19, 2025
Study completion Mar 10, 2026
Sponsor
- Lead sponsor
- Sinovac Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months, up to 59 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The Phase I clinical trial is divided into two parts. The first part uses an open-label design, while the second part uses a randomized, double-blind, and controlled design. The goal of this clinical trial is to evaluate the tolerability and safety of a bivalent (EV71/CA16, Enterovirus 71/Coxsackievirus A16) inactivated enterovirus vaccine (Vero cell) developed by Sinovac. The vaccine will be administered to healthy adults, children aged 6 to 12 years, and children aged 6 to 71 months. The Phase II clinical trial will also use a randomized, double-blind, and controlled design to evaluate the safety and immunogenicity of the same bivalent inactivated enterovirus vaccine (Vero cell) developed by Sinovac. This trial will involve healthy children aged 6 to 71 months.
Conditions
- Hand, Foot and Mouth Disease
- Herpangina
Interventions
low dose Bivalent Enterovirus Vaccine (Vero Cell), InactivatedBiological
Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 480 U-CA16 600 SU/0.5 ml
medium dose Bivalent Enterovirus Vaccine (Vero Cell), InactivatedBiological
Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 960 U-CA16 600 SU/0.5 ml
high dose Bivalent Enterovirus Vaccine (Vero Cell), InactivatedBiological
Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 1920U-CA16 1200SU/0.5ml
Enterovirus type EV71 vaccine (Vero cell), InactivatedBiological
Enterovirus type EV71 vaccine (Vero cell), Inactivated (Sinovac)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ⅰ: Based on adverse events, evaluate the safety of the trial vaccine among participants in different age groupsTime frame: 30 days
- Phase Ⅱ: Evaluate the immunogenicity of the trial vaccine in the target population.Time frame: 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dayao County Center for Disease Control and Prevention
Chuxiong, Yunnan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.